

OPEN ACCESS

EDITED AND REVIEWED BY Nienke Biermasz, Leiden University, Netherlands

*CORRESPONDENCE Sarmed Al-Samerria Salsamerria@arizona.edu

RECEIVED 20 May 2025 ACCEPTED 14 July 2025 PUBLISHED 07 August 2025

CITATION

Al-Samerria S, Xu H, Diaz-Rubio ME, Phelan J, Su C, Ma K, Newen A, Li K, Yamada S, Negron AL, Wondisford F and Radovick S (2025) Corrigendum: Biomarkers of GH deficiency identified in untreated and GH-treated Pit-1 mutant mice. Front. Endocrinol. 16:1631601. doi: 10.3389/fendo.2025.1631601

COPYRIGHT

© 2025 Al-Samerria, Xu, Diaz-Rubio, Phelan, Su, Ma, Newen, Li, Yamada, Negron, Wondisford and Radovick. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Biomarkers of GH deficiency identified in untreated and GH-treated Pit-1 mutant mice

Sarmed Al-Samerria^{1*}, Huiting Xu², M. Elena Diaz-Rubio³, Joseph Phelan², Chi Su², Keer Ma², Anna Newen², Kiana Li², Sayaka Yamada⁴, Ariel L. Negron¹, Fredric Wondisford⁴ and Sally Radovick¹

¹Department of Pediatrics, University of Arizona College of Medicine, Phoenix, AZ, United States, ²Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States, ³Rutgers Cancer Institute, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States, ⁴Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, United States

KEYWORDS

growth hormone deficiency (GHD), biomarkers, PIT-1 mutation, metabolomics, GH treatment, energy metabolism, sex differences

A Corrigendum on

Biomarkers of GH deficiency identified in untreated and GH-treated Pit-1 mutant mice

By Al-Samerria S, Xu H, Diaz-Rubio ME, Phelan J, Su C, Ma K, Newen A, Li K, Yamada S, Negron AL, Wondisford F and Radovick S (2025) Front. Endocrinol. 16:1539797. doi: 10.3389/fendo.2025.1539797

There was a mistake in **Figure 5** as published. **Figure 5** was incorrect and mistakenly showed the same content as Figure 6, rather than the correct figure. The corrected **Figure 5** and its caption appear below.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Al-Samerria et al. 10.3389/fendo.2025.1631601




FIGURE 5

Comparative metabolomic analysis to identify GHD Biomarkers in male mice. This figure examines metabolomic profiles under different GH conditions to identify GHD biomarkers and GH treatment effects. PCA plots (a-c) show metabolic distinctions: (a) GH sufficient (WT) vs. GHD (Mut), (b) GHD (Mut) vs. GH supplemented (Mut + GH), and (c) GH sufficient (WT) vs. GH excess (WT + GH). Volcano plots (d-f) display differentially expressed metabolites based on Log2 fold change and p-values for the same comparisons. Heatmaps (g-i) illustrate key metabolite expression across groups.